GlucoTrack Return on Equity

GlucoTrack (GCTK) currently reports a ROE of -259.51%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore GlucoTrack's ROE history and peer comparisons.

GlucoTrack's ROE of -259.51% is lower than the Healthcare sector average of 21.28%. That is roughly 1319.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but GlucoTrack's current -259.51% should be judged against Healthcare norms (sector average: 21.28%) and against GCTK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -259.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for GlucoTrack, and consider following GCTK for alerts when major investors trade the stock.

GlucoTrack is classified in the Healthcare sector. On ROE, it currently shows -259.51% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GCTK with unrelated industries.